Navigation Links
Epizyme, Inc. Reports Second Quarter 2013 Financial Results
Date:7/31/2013

s of $88.7 million.
  • Continued Progress with EPZ-5676 Development Epizyme is enrolling patients in the dose escalation stage of its Phase 1 study of EPZ-5676 and has added four clinical sites in 2013 for a total of five active sites at this time. The Company expects to initiate an expansion cohort later in the year, limited to patients with MLL-r, in as many as twelve sites in both the United States and Europe. In June, Epizyme scientists published pre-clinical data on EPZ-5676 in the journal Blood, showing the correlation between DOT1L inhibition and anti-proliferative effects specific to MLL-r leukemias, including tumor growth inhibition and durable anti-tumor effects in animal models that were sustained after dosing had been completed. 
  • Companion Diagnostic Collaboration for EPZ-5676 In April, Epizyme announced a collaboration with Abbott Molecular Inc. to develop a molecular companion diagnostic to identify eligible patients for EPZ-5676.
  • Initiation of Phase 1/2 Clinical Trial for EPZ-6438 In June, Epizyme announced the enrollment of its first patient in a Phase 1/2 study of EPZ-6438 (referred to as E7438 by Eisai). Epizyme plans to initiate the Phase 2 portion of this study in 2014.
  • Intellectual Property In April, the Company was granted the first patent covering the composition of matter of EPZ-6438. This patent expires in 2032. In addition, in April, the US Patent and Trademark Office issued a Notice of Allowance for a patent application titled "Diagnostic and Therapeutic Targets for Leukemia" with claims directed to methods of identifying DOT1L inhibitor compounds for the treatment of leukemia. The patent to be issued from this application carries a patent term to at least 2030.
  • Pipeline Development Epizyme continues to conduct preclinical studies to identify additional genetically defined cancers for potential treatment with its therapeutic candi
    '/>"/>

  • SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    2. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
    3. Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope
    4. China Radiotherapy Simulator Market & Digital Radiography 2013 Research Reports Now Available at ReportsnReports.com
    5. Neurocrine Biosciences Reports Second Quarter 2013 Results
    6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
    7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
    8. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
    9. Cepheid Reports 2013 Second Quarter Results
    10. Quest Diagnostics Reports Second Quarter 2013 Financial Results
    11. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... Senior Vice President, General Manager for Clinical ... acumen Elsevier , a world-leading provider ... congratulates Diane Bartoli , Senior Vice President and ... Solutions, for being recognized in the 13 th ... Profiles in Diversity Journal ® . ...
    (Date:11/22/2014)... 2014 Two new educational webinars hosted by ... for ALS research and how the pharmaceutical industry can make ... Bucket Challenge: Where Does the ALS Money Go? , Featuring ... 2014, Time: 1:30pm ET, Register to attend , ... Merit Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General ...
    (Date:11/22/2014)... Prominent academics, leaders of the ... December 3rd at Genetic Rx, a networking conference ... take place at the Joseph B. Martin Conference ... the present and future of genetic medicines—including siRNA, ... editing—as well as the treatment of patients with ...
    (Date:11/22/2014)... (PRWEB) November 21, 2014 RURO, ... solutions provider, has released Limfinity® version 5.1.4. , ... projects of Limfinity® than ever in RURO’s 8 ... and minority framework enhancement. Limfinity® version 5.1.4 is ... above and beyond bug fixes! , Limfinity® 5.1.4 ...
    Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2
    ... Building upon a series of successful preclinical studies, researchers ... today announced the beginning of a Phase 1 clinical trial, ... they developed that can neutralize the Hepatitis C virus (HCV). ... as MBL-HCV1 on July 28, 2009, and the study is ...
    ... ... a new lab?,Now is the perfect time to choose new laboratory equipment.,NuAire, a world leader ... option. To learn more, visit www.nuaire.com/ecopackage . , ... Plymouth, MN (PRWEB) August 14, 2009 -- With such a ...
    ... N.J., Aug. 14 DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... financial results for the second quarter of 2009. , ... National Institutes of Health (NIH) grants, for the second quarter of ... second quarter of 2008. Revenues for the first half of ...
    Cached Biology Technology:First human gets new antibody aimed at hepatitis C virus 2DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 5
    (Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
    (Date:11/18/2014)... 2014   News Highlights: ... develop The Partners Data Lake, an agile data ... Lake will allow researcher and clinicians to explore ... the lives of patients , The Partners ... across the Partners system, breaking down physical barriers ...
    (Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
    Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
    ... the largest DNA data sets for a group of ... collaborators have determined the evolutionary family tree for one ... in the world, the Hawaiian honeycreepers. Not ... that the honeycreeper family originally evolved from, but they ...
    ... , Grainy asteroids and the craters they leave ... Physical Review Letters (forthcoming) It,s generally accepted ... by asteroid collisions. But, why are some craters completely ... projectiles made of globs of granular material appear to ...
    ... to be the exclusive domain of beat poets and wanderers, ... animal kingdom engage in. And it may lead to a ... and Sarah Simmonds from Monash University,s School of Biological Sciences, ... taking the opportunity to jump on board freight and cargo ...
    Cached Biology News:Scientists determine family tree for most-endangered bird family in the world 2Scientists determine family tree for most-endangered bird family in the world 3Crater shapes explained, how carnivorous plants bite, and doubts about faster-than-light neutrinos 2Don't panic: The animal's guide to hitchhiking 2
    Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
    ...
    Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    3M Imidazole Solution 125 ml...
    Biology Products: